Review of Short Phrases and Links|
This Review contains major "Adverse Events"- related terms, short phrases and links grouped together in the form of Encyclopedia article.
- Adverse events were typically mild to moderate and occurred with similar frequency and severity between the nitazoxanide and placebo groups.
- Adverse events were similar in all groups, with transient diarrhoea being the only adverse event seen more frequently with tegaserod than placebo.
- Adverse events were similar between the treatment groups, the most common being headache and abdominal pain.
- Adverse events were comparable between groups; 16.1% of rituximab and 13.6% of placebo patients reported serious events.
- Adverse events were common given the participants' advanced stage of disease, but frequency was similar in the rifaximin and placebo groups (both 80%).
- Patients should be monitored for potential adverse events (see ADVERSE REACTIONS).
- The purpose of this study was to determine the pharmacokinetics of cefepime in this population to optimize dosing and minimize potential adverse events.
- Search terms included, but were not limited to, entecavir, BMS-200475, hepatitis B, pharmacology, pharmacokinetics, adverse events, and therapeutic use.
- Blood and urine samples were obtained pre- and postinfusion for analysis of safety and pharmacokinetics, and data on adverse events were gathered.
- Pediatric CRF Patients: In pediatric patients with CRF on dialysis, the pattern of most adverse events was similar to that found in adults.
- The adverse events most commonly associated with withdrawal in pediatric patients were emotional lability (1.6%), hostility (1.3%), and hyperkinesia (1.1%).
- Benzyl alcohol, a component of this drug product, has been associated with serious adverse events and death, particularly in pediatric patients.
- The most frequent adverse events seen in the placebo-controlled clinical trials in adults with rheumatoid arthritis (HUMIRA vs.
- The most frequent adverse events included tremor, hyperglycemia, hypertension, and infection, but none were severe.
- Frequent adverse events after treatment for childhood-onset differentiated thyroid carcinoma: a single institute experience.
- The most frequent adverse events were nausea, vomiting, and tremor.
- Headache and dizziness were the two most frequent adverse events and were more than twice as frequent in the BiDil group.
- The most frequent adverse events were drowsiness, ataxia, loss of appetite or gastrointestinal symptoms and slowing of mental activity.
- In general, most patients who experienced adverse events during the first eight weeks of these trials no longer experienced them by their last visit.
- The following adverse events were reported, regardless of causality assessment in patients treated with atorvastatin in clinical trials.
- The incidence of adverse events in controlled clinical trials was not affected by gender or age of the patients.
- This section reports additional, less frequent adverse events which occurred among the patients taking clozapine in clinical trials.
- Adverse events were generally similar across treatment and control groups.
- The incidence of serious adverse events and death were balanced between the vaccine and control groups.
- CONCLUSIONS: Subjects in the group treated with policosanol did not have serious adverse events during the 24-week study.
- Policosanol was better tolerated than atorvastatin as revealed by patient withdrawal analysis and overall frequency of adverse events.
- Policosanol was well tolerated, and no significant adverse events were noted.
- The placebo effect in healthy volunteers: Influence of experimental conditions on the adverse events profile during phase I studies.
- In clinical trials, the most serious adverse events reported after treatment were sepsis, gastrointestinal bleeding, and venous thrombosis.
- The most common serious adverse events were pyrexia, mucositis, sepsis, febrile neutropenia, dehydration, dyspnea and thrombocytopenia.
- The following adverse events reported in patients receiving ganciclovir may be potentially fatal: pancreatitis, sepsis, and multiple organ failure.
- Nine patients reported 10 adverse events, none related to treatment.
- Bleeding complications, stroke or intracerebral haemorrhage are potential adverse events for both treatments.
- Zonisamide was withdrawn in two patients due to adverse events.
- Somnolence and fatigue were frequently reported CNS adverse events during clinical trials with zonisamide.
- Use of zonisamide was frequently associated with central nervous system-related adverse events.
- The numbers of dropouts due to adverse events were equal in valacyclovir (2) and placebo (2) groups.
- Clinical improvement of HA and adverse events are 2 outcome measures frequently used in the included trials for symptomatic treatment of migraine attacks.
- Patients were observed for clinical improvement, drug side-effects and any serious or unexpected adverse events.
- Twelve patients withdrew from the study due to adverse events, of which four were judged to be due to study medication.
- Twelve patients (13%) discontinued treatment owing to adverse events.
- Adverse events were experienced by 17 patients taking amitriptyline and 18 patients taking gabapentin.
- Moreover, the overall rate of adverse events was similar in the amitriptyline and gabapentin groups.
- The overall rate of adverse events due to acupuncture was 8.75%.
- Adverse events significantly more common during modafinil compared with placebo treatment were nausea (9% vs.
- The most frequent adverse events with eculizumab were headache, nasopharyngitis and back pain.
- Seven patients in the oxycodone CR group (n=22) and 1 in the placebo group (n=11) withdrew because of adverse events.
- Eleven episodes (18.0%) of adverse events (possibly, probably, definitely related) were reported in seven patients (11.5%).
- In O'Mahony's study [ 27] (80 participants), four subjects reported adverse events during the study.
- Four subjects treated with divalproex ER and three treated with placebo discontinued because of adverse events.
- Both the DEC and albendazole were well tolerated when given alone or in combination, no adverse events being observed.
- Safety was assessed by recording adverse events, laboratory tests, and vital signs at each visit during the study.
- Overall, fewer patients with adverse events were observed in the OLA group (p = 0.04).
- The study drug was discontinued due to adverse events in 2 patients (2.6%) of Group I, and in 3 patients (3.8%) of Group II (p=0.523).
- Two serious adverse events (SAEs) were reported on treatment - neither were considered to be related to the study drug.
- Table 2 lists adverse events that occurred in placebo-controlled clinical trials in patients who took at least 1 dose of study drug.
- Safety analysis was based on the incidence of adverse events.
- Results further showed Prexige and ibuprofen had similar efficacy as well as a comparable incidence of adverse events.
- Adverse events more common in patients given BG00012 than in those given placebo included abdominal pain, flushing, and hot flush.
- The most frequent adverse events thought to be related to atorvastatin were constipation, flatulence, dyspepsia, and abdominal pain.
- Other common adverse events in the three eltrombopag groups were dry mouth, abdominal pain, and nausea.
- There were similar rates of adverse events in the two treatment groups.
- Dextofisopam and placebo had similar rates and types of adverse events, with more events of worsening abdominal pain with dextofisopam (12% vs.
- The use of rescue medication was significantly more for placebo, whereas the number of adverse events was significantly more for sumatriptan.
- Adverse events during rizatriptan were mild and transient; similar events occurred during placebo, with a somewhat reduced incidence.
- The rates of treatment discontinuation because of adverse events were 38.6% and 13.6% in the amitriptyline and pregabalin groups, respectively.
- No serious adverse events resulted in treatment discontinuation.
- Adverse events during exposure to study treatment were obtained by general inquiry and recorded by clinical investigators using their own terminology.
- Adverse events occurring during and up to 1 day after the end of study treatment are shown in Table 2.
- There were no consistent differences in adverse events between patients previously exposed to tegaserod and those treated de novo.
- The most common adverse events, headache and abdominal pain, were more frequent with placebo than with tegaserod.
- There were minimal side effects, no significant changes in safety parameters, and no serious adverse events.
- Safety parameters included adverse events, laboratory parameters, vital signs and physical examination.
- Safety variables were adrenal function, monitoring of adverse events, vital signs, and laboratory parameters.
- The adverse events with an incidence of 1.0% or greater in patients from all studies are given in the table below.
- Even so, few studies have found evidence of an increased risk of adverse events among diabetic divers.
- Adverse events observed in pediatric patients in controlled studies were comparable to those observed in adult patients.
- Outcomes were: (1) 50% or greater reduction in total seizure frequency; (2) treatment withdrawal; (3) adverse events.
- Adverse events were reported in 52% (n=263) of patients receiving DETROL LA and in 49% (n=247) of patients receiving placebo.
- Zonegran was generally well-tolerated at all doses, with adverse events occurring in a similar proportion to patients receiving placebo.
- There was no difference in adverse events between the lidocaine and placebo groups, and the most commonly reported events were rash and pruritus.
- We did not find significant effects of methotrexate on pruritus, fatigue, liver complications, liver biochemistry, liver histology, or adverse events.
- Consistent with previous studies evaluating mipomersen, the most commonly observed adverse events were injection site reactions and flu-like symptoms.
- McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials.
- Therefore, we have conducted a systematic review and meta-analysis for both efficacy and adverse events of analgesic therapy for PHN.
- Figure 4: Meta-analysis of serious adverse events and death in selected studies of prophylactic vaccination against HPV-related infection and disease.
- Dose-related adverse events in patients on BG00012 were headache, fatigue, and feeling hot.
- Adverse events occurred with similar incidence in all treatment groups, with no dose-related increases in any event.
- The overall frequency of adverse events was not dose-related.
- Four patients discontinued treatment due to adverse events.
- Humans > Health > Diseases > Patients
- Society > Humans > Medicine > Placebo
- Evaluation > Analysis > Tests > Treatment Groups
* Adverse Effects
* Adverse Events Associated
* Causal Relationship
* Clinical Studies
* Common Adverse Events
* Dose Reduction
* Extrapyramidal Symptoms
* Injection Site
* Laboratory Values
* Overall Incidence
* Own Choosing
* Patient Population
* Placebo-Treated Patients
* Placebo Group
* Placebo Groups
* Placebo Patients
* Safety Profile
* Secondary Outcomes
* Serious Adverse Events
* Side Effects
* Significant Difference
* Significant Differences
* Similar Frequency
* Three Patients
* Three Treatment Groups
* Treatment Arms
* Treatment Group
* Treatment Groups
* Treatment Studies
* Vital Signs
Books about "Adverse Events" in